Tuesday, July 18, 2017 4:46:13 PM
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12177878
Recent PCSA News
- Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results • GlobeNewswire Inc. • 10/30/2024 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:05:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:36:29 PM
- Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer • GlobeNewswire Inc. • 10/02/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:50:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:48:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:47:53 PM
- Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 12:00:21 PM
- Processa Pharmaceuticals Provides Product Pipeline and Financial Update • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri • GlobeNewswire Inc. • 08/19/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:15:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:34:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:31:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:28:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:12:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 12:00:21 PM
- Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer • GlobeNewswire Inc. • 07/30/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/22/2024 09:59:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 12:00:22 PM
- Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 06/11/2024 06:19:42 PM
- Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer • GlobeNewswire Inc. • 06/11/2024 12:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/29/2024 04:15:13 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/28/2024 08:49:30 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM